24 results
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
with the wind down of those Legacy Assets, and costs associated with furthering our IBD pipeline candidates. Wind down costs included final patient visits
POS AM
SYRE
Spyre Therapeutics Inc.
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
associated with our Legacy Assets, costs associated with the wind down of those Legacy Assets, and costs associated with furthering our IBD pipeline … candidates. Wind down costs included final patient visits, collection and analysis of final patient data, the creation and submission of final research
POS AM
SYRE
Spyre Therapeutics Inc.
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
to clinical trial costs associated with our Legacy Assets, costs associated with the wind down of those Legacy Assets, and costs associated with furthering … our IBD pipeline candidates. Wind down costs included final patient visits, collection and analysis of final patient data, the creation and submission
CORRESP
y9tgi8 iqrpgjg9oqcl
26 Oct 23
Correspondence with SEC
12:00am
CORRESP
hv6 e00ej6l3q3f4h7
8 Sep 23
Correspondence with SEC
12:00am
8-K
EX-2.1
ymu c11naes
23 Jun 23
Entry into a Material Definitive Agreement
9:16am